Status:
COMPLETED
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
Lead Sponsor:
Indiana University
Collaborating Sponsors:
Abbott
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to study the effects of Paricalcitol (Zemplar) on kidney functioning. The investigators hypothesize that the increase in serum creatinine observed in recent paricalcitol t...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Stage 3 or 4 CKD
- Ability to give informed consent
Exclusion
- Serum Calcium \> 10 g/dL
- Serum Phosphorous \> 6 g/dL
- On \> 400 units/d Vitamin D therapy
- Receiving cimetidine, triamterene, or trimethoprim, drugs that block creatinine secretion
- On vitamin D receptor activators (paricalcitol, calcitriol or Zemplar)
- Allergic to radiocontrast dye
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01163162
Start Date
August 1 2010
End Date
June 1 2011
Last Update
May 21 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roudebush VA Medical Center
Indianapolis, Indiana, United States, 46202